创伤性脑损伤中的脑自动调节:超低频压力反应指数与颅内压在不同年龄组中的表现
该研究纳入263例创伤性脑损伤(TBI)患者,其中儿童(≤16岁)占17.5%、成人(>16且<70岁)占60.5%、≥70岁占22.0%,评估超低频压力反应指数(UL-PRx,0.0033 Hz、5分钟平均)对12个月结局(GOSE)的预测能力,并与IMPACT模型比较。院内死亡率为25.9%,12个月死亡率为32.7%,60.0%患者12个月结局不良。单因素分析显示ICP、CPP、UL-PRx和ΔCPPopt均与12个月结局相关;平均ICP约20-22和平均UL-PRx约0.30的阈值在除>70岁外的所有年龄组获确认;UL-PRx经IMPACT模型校正后仍与12个月结局显著相关,且在各年龄组均获确认;UL-PRx与CPPopt相关。作者认为UL-PRx是评估脑自动调节和预测TBI结局的有价值工具,并可能支持更靶向的治疗策略。
要点
- 在263例TBI患者中,平均UL-PRx约0.30的阈值在除>70岁以外的各年龄组均获确认,可作为床旁评估脑自动调节的参考界值。
- 平均ICP约20-22的阈值在除>70岁以外的各年龄组获确认,>70岁患者中该阈值未获确认。
- UL-PRx经IMPACT模型校正后仍与12个月结局显著相关,且该关联在所有年龄组均获确认。
- 单因素分析中ICP、CPP、UL-PRx和ΔCPPopt均与12个月结局相关。
- UL-PRx与CPPopt相关,作者认为这提示可能支持更靶向的治疗策略。
适用人群与场景
- 纳入263例创伤性脑损伤(TBI)患者,儿童(≤16岁)占17.5%,成人>16且<70岁占60.5%,≥70岁占22.0%。
- 研究场景为TBI患者的床旁脑自动调节评估与12个月结局预测。
诊断标准与关键阈值
- 平均ICP阈值约20-22在除>70岁以外的所有年龄组获确认。
- 平均UL-PRx阈值约0.30在除>70岁以外的所有年龄组获确认。
- UL-PRx数据采集为低采样率0.0033 Hz、5分钟平均。
研究设计与关键结果
- 研究纳入263例TBI患者,院内死亡率为25.9%,12个月死亡率为32.7%,60.0%患者12个月结局不良(GOSE)。
- 单因素分析显示ICP、CPP、UL-PRx和ΔCPPopt均与12个月结局相关。
- 平均ICP约20-22和平均UL-PRx约0.30的阈值在除>70岁以外的所有年龄组获确认。
- 平均UL-PRx经IMPACT模型校正后仍与12个月结局显著相关,且该关联在所有年龄组均获确认。
- UL-PRx与CPPopt相关。
证据类型、等级与局限
- 证据类型:基于263例TBI患者的临床研究(ClinicalTrials.gov注册号NCT05043545,主要研究者Paolo Gritti,注册日期2021年8月21日)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为UL-PRx是评估脑自动调节和预测TBI患者结局的有价值工具,其结果强调了UL-PRx的潜在临床效用及其在不同年龄组间的适应性,即使经IMPACT模型校正后亦然。
- 作者认为UL-PRx与CPPopt的相关性提示可能支持更靶向的治疗策略。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The ultra-low-frequency pressure reactivity index (UL-PRx) has been established as a surrogate method for bedside estimation of cerebral autoregulation (CA). Although this index has been shown to be a predictor of outcome in adult and pediatric patients with traumatic brain injury (TBI), a comprehensive evaluation of low sampling rate data collection (0.0033 Hz averaged over 5 min) on cerebrovascular reactivity has never been performed.
OBJECTIVE: To evaluate the performance and predictive power of the UL-PRx for 12-month outcome measures, alongside all International Mission for Prognosis and Analysis of Clinical Trials (IMPACT) models and in different age groups. To investigate the potential for optimal cerebral perfusion pressure (CPPopt).
METHODS: Demographic data, IMPACT variables, in-hospital mortality, and Glasgow Outcome Scale Extended (GOSE) at 12 months were extracted. Filtering and processing of the time series and creation of the indices (cerebral intracranial pressure (ICP), cerebral perfusion pressure (CPP), UL-PRx, and deltaCPPopt (ΔCPPopt and CPPopt-CPP)) were performed using an in-house algorithm. Physiological parameters were assessed as follows: mean index value, % time above threshold, and mean hourly dose above threshold.
RESULTS: A total of 263 TBI patients were included: pediatric (17.5% aged ≤ 16 y) and adult (60.5% aged > 16 and < 70 y and 22.0% ≥ 70 y, respectively) patients. In-hospital and 12-month mortality were 25.9% and 32.7%, respectively, and 60.0% of patients had an unfavorable outcome at 12 months (GOSE). On univariate analysis, ICP, CPP, UL-PRx, and ΔCPPopt were associated with 12-month outcomes. The cutoff of ~ 20-22 for mean ICP and of ~ 0.30 for mean UL-PRx were confirmed in all age groups, except in patients older than 70 years. Mean UL-PRx remained significantly associated with 12-month outcomes even after adjustment for IMPACT models. This association was confirmed in all age groups. UL-PRx resulted associate with CPPopt.
CONCLUSIONS: The study highlights UL-PRx as a tool for assessing CA and valuable outcome predictor for TBI patients. The results emphasize the potential clinical utility of the UL-PRx and its adaptability across different age groups, even after adjustment for IMPACT models. Furthermore, the correlation between UL-PRx and CPPopt suggests the potential for more targeted treatment strategies.
TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT05043545, principal investigator Paolo Gritti, date of registration 2021.08.21.
参考来源
- Gritti P, Bonfanti M, Zangari R, et al. Cerebral autoregulation in traumatic brain injury: ultra-low-frequency pressure reactivity index and intracranial pressure across age groups. Crit Care. 2024. PMID: 38263241. doi:10.1186/s13054-024-04814-5
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。